Drug discovery

#Academic #Biomarkers #Business #Cellular assays #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Molecular medicine #Screening #Stem cells #Target validation #Therapeutics #Translational #Translational chemistry

Mobidiag receives second tranche of financing from European Investment Bank

17 June 2020 This is the second tranche of growth capital loan signed with the European Investment Bank in May 2019. The new funds will be used for the development, manufacture and commercialisation of in vitro diagnostics for infectious diseases Mobidiag, a revenue generating, molecular diagnostics company with… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular assays #Drug discovery #Enabling technologies #Lead discovery #Precision medicine #Regenerative Medicine #Screening #System biology #Systems biology #Toxicology

Qkine to accelerate commercial operations with US$1.9 million investment

09 June, 2020 The specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications announced the successful closure of a £1.5 million (US$1.9 million) series A investment round to accelerate the global scale-up of its commercial operations. According to Cambridge based Qkine, the funding… Read More

#News

#Drug discovery

Guide: 5 Ways Biophysical tools help brain studies

Guide: 5 Ways Biophysical tools help brain studies Sponsored by Nanotemper, 8 June 2020 Learn how scientists gain insight into the molecular mechanisms of protein misfolding and aggregation- a hallmark of neurodegenerative diseases by using biophysical tools to analyze molecular interactions and thermal stability. Read More

#DDW eBooks #Resources

#Automation / robotics #Business #Drug discovery #Lead discovery #Screening

MolPort and BioAscent partnership reaches 100-project milestone

27 May, 2020 Compound sourcing specialist MolPort has announced the successful completion of 100 projects in partnership with BioAscent, one of the leading providers of integrated drug discovery services based in the UK. Through their collaborative efforts, MolPort and BioAscent said they have significantly enhanced customer service by… Read More

#News

#Drug development #Drug discovery #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #RNA #Screening

New antibody internalization advanced screening method provides greater speed & insight

New antibody internalization advanced screening method provides greater speed & insight 26 May 2020 Sponsored by Sartorius Researchers abilities to improve the breadth of therapeutic antibodies have been aided by innovative technologies for antibody discovery, for instance, through humanization of mouse antibodies and phage display. However, advanced antibody… Read More

#Editor's Choice #Resources

#Academic #AI / data analytics / healthtech / informatics #Biomarkers #Business #Chemistry #Clinical specialities #Drug development #Drug discovery #Medicinal chemistry #RNA #System biology #Systems biology #Therapeutics

What will post-Covid-19 biotechnology look like?

Collaborative Drug Discovery (CDD), owner of the CDD Vault, a comprehensive drug discovery informatics platform for research laboratories, has asked researchers what they think biotechnology world will look like after Covid-19. A few responses are listed below. “Covid-19 may be the tipping point that shifts us from the… Read More

#Covid-19 #News

#Academic #Biomarkers #Drug discovery #Drug targets #Immunology #Immunology / Virology & Vaccines #Pathology #Pharmokinetics #Stem cells

Creoptix collaboration to characterise anti-SARS-CoV-2 antibodies

15 May, 2020 The Swiss next-generation bioanalytical instruments specialist announced a collaboration with Adriano Aguzzi, Professor for Neuropathology, University of Zurich, to characterise immunological responses to SARS-CoV-2 such as IgA, IgM and IgG antibodies, which signal whether an individual has been exposed to the coronavirus. The collaboration aims… Read More

#News

#Business #Drug discovery

C4X Discovery Holdings succeeds in raising US$1.97 million

12 May, 2020 The UK based drug discovery company said it has successfully completed the Placing announced earlier. C4X Discovery Holdings said that a total of 10,836,700 Placing Shares have been placed by Panmure Gordon (UK) at the Issue Price of £0.15 (US$0.18) per new Ordinary Share to… Read More

#News

#Animal models #Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #Genetics / genomes #Immunology / Virology & Vaccines #Regulatory #RNA

Insect-based technology for human vaccines

06 May, 2020 Spain based private biotechnology company Algenex announced that it is advancing the application of its CrisBio-based vaccine production technology in human health. Building on its expertise in the production of proteins for veterinary vaccines, Algenex said it has started to produce biotechnology products for the… Read More

#News

#Biologics / Biotechnology #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Immunology / Virology & Vaccines #Precision medicine #RNA

Oxford University and AstraZeneca partner for COVID-19 vaccine candidate

Oxford University and its spin-out company Vaccitech announced an agreement with UK based biopharmaceutical specialist AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate, currently being trialled by the University. With immediate effect, the partnership is said to allow for rapid vaccination… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The CRISPR revolution arrives in immuno-oncology

The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 – Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 – Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic… Read More

#Exclusive Content

#Academic #Assay development optimisation & technology #Business #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #RNA #Target validation #Therapeutics

The Reproducibility Crisis – How did we get here?

By Dr William Olds and Dr Deepa Shankar While the antibody market has evolved into a multibillion-dollar industry enabling the discovery of cures, disease diagnosis and basic science acceleration, this has allowed low quality antibodies to hit the market. With a large crisis in reproducibility, the need for… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Oncology #PCR #Precision medicine #Regulatory #RNA #Therapeutics #Translational #Translational chemistry

Antimicrobial resistance threatens to undermine our healthcare system

Antimicrobial resistance threatens to undermine our healthcare system By Dr Peter Jackson Volume 21 Issue 2 – Spring 2020 The immediate global challenge to human health and our economic stability due to coronavirus acts as a stark reminder that infectious disease preparedness cannot be ignored. Read More

#Exclusive Content

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Medicinal chemistry #Organic chemistry #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

How sharing compound solubility data can advance drug discovery

By Andrii Lozoniuk Volume 21 Issue 2 – Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemistry #Drug development #Drug discovery #Drug targets #Gene editing #Genetics / genomes #Genomics #High throughput screening #Molecular medicine #Oncology #Orphan drugs #PCR #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Target discovery and drug development what comes after CRISPR?

Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 – Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have… Read More

#Exclusive Content